{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:19:14Z","timestamp":1784297954844,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.clml.2017.06.002","type":"journal-article","created":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T14:16:34Z","timestamp":1497968194000},"page":"767-773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["FLAG-Ida Regimen as Bridge Therapy to Allotransplantation in Refractory\/Relapsed Acute Myeloid Leukemia Patients"],"prefix":"10.1016","volume":"17","author":[{"given":"Mario","family":"Delia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Pastore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Carluccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crescenza","family":"Pasciolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ricco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella Russo","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Casieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mestice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7926-6052","authenticated-orcid":false,"given":"Francesco","family":"Albano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgina","family":"Specchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.06.002_bib1","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.06.002_bib2","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.002_bib3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"Dohner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.002_bib4","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.bbmt.2014.10.025","article-title":"Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy","volume":"21","author":"Othus","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2017.06.002_bib5","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V88.2.756.bloodjournal882756","article-title":"A\u00a0stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia","volume":"88","author":"Estey","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.002_bib6","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/sj.leu.2401568","article-title":"Treatment of relapsed and refractory acute myelogenous leukemia","volume":"14","author":"Estey","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.06.002_bib7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","article-title":"How I treat refractory and early relapsed acute myeloid leukemia","volume":"126","author":"Thol","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.002_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.1995.13.1.11","article-title":"Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial","volume":"13","author":"Archimbaud","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.002_bib9","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1365-2141.2011.08831.x","article-title":"Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF): a phase 2 trial of the FLT3 inhibitor lestaurtinib priming for relapsed and refractory acute myeloid (CEP701) as first-line treatment for older leukaemia","volume":"155","author":"Becker","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.06.002_bib10","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/ajh.23308","article-title":"Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients","volume":"87","author":"Scappini","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.06.002_bib11","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.002_bib12","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.06.002_bib13","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.06.002_bib14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox","year":"1972","journal-title":"J\u00a0R Stat Soc"},{"key":"10.1016\/j.clml.2017.06.002_bib15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.clml.2017.06.002_bib16","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ajh.24439","article-title":"CME information: acute myeloid leukemia: 2016 update on risk-stratification and management","volume":"91","author":"Tefferi","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.06.002_bib17","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1182\/blood.V80.4.1090.1090","article-title":"Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy","volume":"80","author":"Biggs","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.002_bib18","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","article-title":"Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure","volume":"28","author":"Duval","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.002_bib19","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/bmt.2015.6","article-title":"Indications for allo- and auto-SCT for hematological diseases, solid tumours and immune disorders: current practice in Europe, 2015","volume":"50","author":"Sureda","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2017.06.002_bib20","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.3324\/haematol.2014.118570","article-title":"Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia","volume":"100","author":"Araki","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.06.002_bib21","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00277-003-0624-2","article-title":"FLAG-Ida in the treatment of refractory\/relapsed acute myeloid leukemia: single-center experience","volume":"82","author":"Pastore","year":"2003","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2017.06.002_bib22","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1182\/blood-2005-08-3167","article-title":"Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)","volume":"107","author":"Thiede","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.002_bib23","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1158\/0008-5472.CAN-05-4316","article-title":"Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution","volume":"66","author":"Chou","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2017.06.002_bib24","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1200\/JCO.2011.35.7525","article-title":"Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment","volume":"29","author":"Walter","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.002_bib25","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2005-10-4165","article-title":"Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation","volume":"108","author":"Schmid","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.002_bib26","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1002\/cncr.25263","article-title":"Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group","volume":"116","author":"Rowe","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.06.002_bib27","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)- specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.002_bib28","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","article-title":"Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation","volume":"32","author":"Sorror","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.002_bib29","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s12185-017-2198-0","article-title":"Clofarabine-based chemotherapy as a bridge to transplant in the setting of refractory or relapsed acute myeloid leukemia, after at least one previous unsuccessful salvage treatment containing fludarabine: a single institution experience","volume":"105","author":"Molteni","year":"2017","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2017.06.002_bib30","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1038\/leu.2012.105","article-title":"High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses","volume":"26","author":"Metzelder","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.06.002_bib31","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood.V122.21.494.494","article-title":"Results of a phase 2 randomized, open-label, study of lower doses of quizartinib (AC220; ASP2689) in subjects with FLT3-ITD positive relapsed or refractory acute myeloid leukemia (AML)","volume":"122","author":"Cortes","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.002_bib32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/2040620714532123","article-title":"The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond","volume":"5","author":"Wander","year":"2014","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2017.06.002_bib33","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/bjh.12691","article-title":"Antibody therapy for acute myeloid leukaemia","volume":"164","author":"Gasiorowski","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.06.002_bib34","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1182\/blood-2015-01-561373","article-title":"Current challenges in clinical development of\u00a0\u201ctargeted therapies\u201d: the case of acute myeloid leukemia","volume":"125","author":"Estey","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.002_bib35","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1517\/14656566.2015.981527","article-title":"New treatment for acute myelogenous leukemia","volume":"16","author":"DiNardo","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clml.2017.06.002_bib36","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMra1112635","article-title":"Targeting epigenetic readers in cancer","volume":"367","author":"Dawson","year":"2012","journal-title":"N\u00a0Engl J Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017302859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017302859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:29:44Z","timestamp":1761870584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017302859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S2152265017302859"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.06.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FLAG-Ida Regimen as Bridge Therapy to Allotransplantation in Refractory\/Relapsed Acute Myeloid Leukemia Patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}